Skip to main content
IDXX
NASDAQ Life Sciences

IDEXX Reports Strong 2025 Financials with Double-Digit Revenue Growth and Increased Share Repurchases

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$635.66
Mkt Cap
$50.758B
52W Low
$356.14
52W High
$769.98
52W Position info
78% above low
Off High info
17% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

IDXX sits 78% above its 52-week low of $356.14.

Summary

IDEXX Laboratories Inc. delivered robust financial results for fiscal year 2025, reporting significant increases in revenue, net income, and EPS, alongside substantial share repurchases.


Key Events · Earnings and Guidance · IDXX

  • Strong Financial Performance

    Total revenue grew 10.4% to $4.3 billion, net income rose to $1.06 billion, and diluted EPS reached $13.08 for fiscal year 2025, demonstrating robust operational execution.

  • Significant Share Repurchases

    The company repurchased $1.23 billion of common stock in 2025, a substantial increase from the prior year, reflecting a strong commitment to returning value to shareholders.

  • Healthy Financial Position

    IDEXX maintains a strong balance sheet with a consolidated leverage ratio of 0.54, well below the 3.5-to-1 covenant, and $850.2 million in remaining borrowing availability under its credit facility.

  • Positive 2026 Outlook

    Management anticipates favorable foreign currency impacts to increase 2026 revenues by approximately $28 million, operating profit by $22 million, and diluted EPS by $0.22 per share.


Analysis · IDXX · Life Sciences

IDEXX Laboratories Inc. has reported robust financial performance for fiscal year 2025, marked by significant growth across key metrics and a substantial return of capital to shareholders. The Companion Animal Group (CAG) segment, the company's primary business, was a major driver of this growth. The company's strong liquidity and low leverage ratio indicate a healthy financial position, providing flexibility for future strategic initiatives. The outlook for 2026, including anticipated positive foreign currency impacts, suggests continued growth. The resolution of a prior litigation matter, with the $80 million payment having been accrued in previous years, removes a potential overhang.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IDXX was trading at $635.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.8B. The 52-week trading range was $356.14 to $769.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IDXX - Latest Insights

IDXX
Nov 02, 2026, 4:29 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $670.00
Real-time Price: $674.29 info
Change: +$4.28 (+0.64%) info
Market Cap: $53.24B info
IDXX
Nov 02, 2026, 11:45 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $659.20
Real-time Price: $674.29 info
Change: +$15.09 (+2%) info
Market Cap: $53.24B info
IDXX
Nov 02, 2026, 6:45 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $555.00
Real-time Price: $674.29 info
Change: +$119.28 (+21%) info
Market Cap: $53.24B info
IDXX
Nov 02, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $544.00
Real-time Price: $674.29 info
Change: +$130.28 (+24%) info
Market Cap: $53.24B info
IDXX
Sep 16, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $505.26
Real-time Price: $674.29 info
Change: +$169.02 (+33%) info
Market Cap: $53.24B info